Corvus Pharmaceuticals announced interim data on December 18, 2024, from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The data from Cohort 1 (100 mg oral twice per day) demonstrated a favorable safety and efficacy profile.
At day 28, the soquelitinib group (n=12) showed a mean EASI score reduction of 55.9%, compared to a 27.0% reduction in the placebo group (n=4). By day 58, continued improvement was observed in the soquelitinib group with a mean EASI reduction of 69.1% (n=10), versus 19.1% for placebo. No significant safety issues or dose-limiting toxicities were reported.
Concurrently, the company announced that Samlyn Capital, a warrant holder, exercised 3,633,978 common stock warrants, generating approximately $12.7 million in cash proceeds. This early exercise strengthens the company's liquidity and provides additional funding for its ongoing clinical development programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.